Literature DB >> 21636346

[Pathogenesis and management of refractory malignant ascites].

Esma Saâda1, Philippe Follana, Fréderic Peyrade, Véronique Mari, Eric François.   

Abstract

Malignant ascites are the cancer-associated accumulation of fluids in the peritoneal cavity. The neoplasms most frequently associated with ascites are ovarian, breast, colon, stomach and pancreas adenocarcinomas. Symptoms are abdominal distention, nausea, vomiting, anorexia, dyspnea and limbs oedemas. Several pathophysiological mechanisms might be implicated such as peritoneal carcinomatosis, lymphatic vessels' obstruction, portal hypertension or heart failure. Its diagnosis is most often performed in a context of already known neoplasia. Malignant ascites are associated with a pejorative evolution. Ascites which cannot be mobilized or show early recurrence and cannot be prevented by medical treatment are defined as refractory ascites. Therefore, management of refractory malignant ascites takes place in the context of palliative care and aims at improving the quality of life of these patients. This review lists the current data reported on the pathophysiology of malignant ascites and describes the present and future options for refractory malignant ascites management.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21636346     DOI: 10.1684/bdc.2011.1373

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  6 in total

1.  Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites.

Authors:  Hongmei Wei; Shukui Qin; Xiaojin Yin; Yali Chen; Haiqing Hua; Lin Wang; Ningrong Yang; Yingxia Chen; Xiufeng Liu
Journal:  Oncol Lett       Date:  2015-04-21       Impact factor: 2.967

2.  The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma: A Case-Control Study.

Authors:  Marina Baretti; Bhargavi Pulluri; Hua-Ling Tsai; Amanda L Blackford; Christopher L Wolfgang; Daniel Laheru; Lei Zheng; Joseph Herman; Dung T Le; Amol K Narang; Ana de Jesus-Acosta
Journal:  Pancreas       Date:  2019-04       Impact factor: 3.243

3.  Management of non-ovarian cancer malignant ascites through indwelling catheter drainage.

Authors:  Xiaoli Gu; Yuanyuan Zhang; Menglei Cheng; Minghui Liu; Zhe Zhang; Wenwu Cheng
Journal:  BMC Palliat Care       Date:  2016-04-21       Impact factor: 3.234

4.  Expression of Adiponectin Receptor-1 and Prognosis of Epithelial Ovarian Cancer Patients.

Authors:  Xiahui Li; Zhe Yu; Liping Fang; Fang Liu; Kui Jiang
Journal:  Med Sci Monit       Date:  2017-03-30

5.  Endoscopic ultrasound-guided placement of plastic pigtail stents for the drainage of refractory malignant ascites.

Authors:  Rafael Romero-Castro; Victoria Alejandra Jimenez-Garcia; Jaime Boceta-Osuna; Luis Castilla-Guerra; Francisco Pellicer-Bautista; Angel Caunedo-Alvarez; Juan Manuel Herrerias-Gutierrez; Manuel Romero-Gómez; Marc Giovannini
Journal:  Endosc Int Open       Date:  2017-10-27

6.  Determination of the optimal volume of ascitic fluid for the precise diagnosis of malignant ascites.

Authors:  Feifei Zhang; Zhenning Feng; Yichi Zhang; Zishuai Liu; Xiaoli Sun; Shizhu Jin
Journal:  Saudi J Gastroenterol       Date:  2019 Sep-Oct       Impact factor: 2.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.